US 10617709
miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
granted A61KA61K31/7105A61K31/713
Quick answer
US patent 10617709 (miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers) held by The Board of Regents of the University of Texas System expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Apr 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/7105, A61K31/713, A61K45/06, A61P